ANNX

Annexon, Inc. [ANNX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ANNX Stock Summary

Top 10 Correlated ETFs

ANNX


Top 10 Correlated Stocks

ANNX


In the News

11:55 08 Jun 2023 ANNX

Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why

Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.

11:52 08 Jun 2023 ANNX

Why Shares of Annexon Are Plummeting Thursday

Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February.

09:23 08 Jun 2023 ANNX

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.

07:47 08 Jun 2023 ANNX

May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but peak gains were in COIN +14.4% and TLRY +7.1%. The Active ETF portfolio continues with YTD gains at +14.2%.

08:01 08 Jun 2023 ANNX

April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge

April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge.

06:30 08 Jun 2023 ANNX

Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco.

12:29 08 Jun 2023 ANNX

Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues

Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain.  The 28 patients were dosed for six months and followed for three more.

06:30 08 Jun 2023 ANNX

Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.

07:30 08 Jun 2023 ANNX

Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings

BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the company will present data from across its complement-targeted pipeline at several upcoming medical meetings.

06:30 08 Jun 2023 ANNX

Annexon Biosciences to Participate in Upcoming May Investor Conferences

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:

ANNX Financial details

Company Rating
Neutral
Market Cap
158.19M
Income
-138.55M
Revenue
0
Book val./share
2.91
Cash/share
3.09
Dividend
-
Dividend %
-
Employees
80
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-1.66
Forward P/E
-
PEG
0.56
P/S
-
P/B
1.07
P/C
0.95
P/FCF
-1.37
Quick Ratio
9.95
Current Ratio
10.14
Debt / Equity
0.25
LT Debt / Equity
0.14
-
-
EPS (TTM)
-2.38
EPS next Y
-
EPS next Q
-
EPS this Y
-25.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
9.09%
-
-
-
-
SMA20
-50%
SMA50
-25%
SMA100
-50%
Inst Own
98.7%
Inst Trans
28.06%
ROA
-52%
ROE
-63%
ROC
-0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
53.08M
Shs Float
29.78M
-
-
-
-
Target Price
-
52W Range
2.07-7.65
52W High
-57.93%
52W Low
+47.25%
RSI
36
Rel Volume
1.83
Avg Volume
797.13K
Volume
1.46M
Perf Week
-1.17%
Perf Month
-45.96%
Perf Quarter
-47.03%
Perf Half Y
-48.78%
-
-
-
-
Beta
0.470865
-
-
Volatility
0.09%, 1.34%
Prev Close
-5.61%
Price
2.945
Change
-9.1%

ANNX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-1.6-2.83-3.7-3.39-2.53
Operating cash flow per share
-1.5-2.16-3.13-2.77-2.13
Free cash flow per share
-1.5-2.18-3.16-2.81-2.25
Cash per share
3.863.3520.76.334.44
Book value per share
3.313.3220.36.054.23
Tangible book value per share
3.313.3220.36.054.23
Share holders equity per share
3.313.3220.36.054.23
Interest debt per share
00.3600.850.67
Market cap
203.39M232.98M424.57M440.25M282.66M
Enterprise value
159.22M189.04M156M400M175.5M
P/E ratio
-11.11-6.27-6.77-3.39-2.04
Price to sales ratio
00000
POCF ratio
-11.83-8.22-8-4.15-2.43
PFCF ratio
-11.82-8.14-7.93-4.09-2.3
P/B Ratio
5.375.351.231.91.22
PTB ratio
5.375.351.231.91.22
EV to sales
00000
Enterprise value over EBITDA
-8.94-5.9-2.46-3.06-1.21
EV to operating cash flow
-9.26-6.67-2.94-3.77-1.51
EV to free cash flow
-9.25-6.6-2.91-3.71-1.43
Earnings yield
-0.09-0.16-0.15-0.3-0.49
Free cash flow yield
-0.08-0.12-0.13-0.24-0.43
Debt to equity
0.270.150.030.240.23
Debt to assets
0.210.130.030.190.19
Net debt to EBITDA
2.481.374.230.310.74
Current ratio
13.749.2133.3311.3911.1
Interest coverage
0-6.98061.05-39.87
Income quality
0.940.760.840.810.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.010.010.020.06
Capex to revenue
00000
Capex to depreciation
-0.03-0.54-0.7-0.77-3.1
Stock based compensation to revenue
00000
Graham number
10.9114.5541.0821.4915.51
ROIC
0.460.810.34-1.0360.11
Return on tangible assets
-0.38-0.75-0.18-0.45-0.49
Graham Net
2.982.8720.024.93.45
Working capital
42.38M40.48M343.39M225.95M225.74M
Tangible asset value
37.88M43.53M344.28M231.91M231.19M
Net current asset value
35.44M39.04M342.34M192.56M194.2M
Invested capital
0000.150.14
Average receivables
0152K41K1.5K0
Average payables
01.82M3.05M7.44M9.28M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.48-0.85-0.18-0.56-0.6
Capex per share
0-0.02-0.03-0.04-0.12

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
00000
Net income per share
-0.92-0.96-0.5-0.44-0.48
Operating cash flow per share
-0.79-0.73-0.45-0.38-0.45
Free cash flow per share
-0.92-0.75-0.45-0.38-0.45
Cash per share
5.364.63.933.353.09
Book value per share
5.24.363.83.192.91
Tangible book value per share
5.24.363.83.192.91
Share holders equity per share
5.24.363.83.192.91
Interest debt per share
0.890.890.510.490.4
Market cap
105.28M145.46M424.27M374.15M284.34M
Enterprise value
26.63M74.98M247.32M266.98M172.73M
P/E ratio
-0.75-0.99-3.12-2.92-2
Price to sales ratio
00000
POCF ratio
-3.48-5.16-13.81-13.79-8.62
PFCF ratio
-2.97-5.01-13.74-13.64-8.58
P/B Ratio
0.520.871.631.621.32
PTB ratio
0.520.871.631.621.32
EV to sales
00000
Enterprise value over EBITDA
-0.76-2.03-6.96-7.28-4.19
EV to operating cash flow
-0.88-2.66-8.05-9.84-5.24
EV to free cash flow
-0.75-2.58-8.01-9.74-5.21
Earnings yield
-0.34-0.25-0.08-0.09-0.13
Free cash flow yield
-0.34-0.2-0.07-0.07-0.12
Debt to equity
0.250.310.20.230.25
Debt to assets
0.20.240.170.190.2
Net debt to EBITDA
2.251.914.982.922.71
Current ratio
12.398.9513.5911.110.14
Interest coverage
-668.42-137.53-35.54-15.8713.3
Income quality
0.860.760.880.790.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.170.030.010.010
Capex to revenue
00000
Capex to depreciation
-10.07-1.59-0.33-0.53-0.26
Stock based compensation to revenue
00000
Graham number
10.359.686.515.645.62
ROIC
-2.28-31.60.314.51.27
Return on tangible assets
-0.14-0.17-0.11-0.11-0.13
Graham Net
4.063.243.172.612.36
Working capital
194.2M161.12M254.56M225.74M209.6M
Tangible asset value
200.61M168.04M260.6M231.19M214.86M
Net current asset value
161.3M128.71M222.66M194.2M178.62M
Invested capital
0.170.20.130.140.15
Average receivables
00000
Average payables
10.27M9.84M8.61M7.17M8.88M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.18-0.22-0.13-0.14-0.17
Capex per share
-0.14-0.02000

ANNX Frequently Asked Questions

What is Annexon, Inc. stock symbol ?

Annexon, Inc. is a US stock , located in Brisbane of Ca and trading under the symbol ANNX

What is Annexon, Inc. stock quote today ?

Annexon, Inc. stock price is $2.945 today.

Is Annexon, Inc. stock public?

Yes, Annexon, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap